Endovasc Appoints Two Prominent Scientists to Scientific Advisory Board.

MONTGOMERY, Texas--(BUSINESS WIRE)--March 16, 1999--Endovasc Ltd. Inc. (OTC BB:ENDV) today announced the addition of two more prominent scientists to its Scientific Advisory Board. Appointed was James D. Regan Ph.D., formerly Senior Investigator and Group Leader for Medical and Molecular Genetics at Oak Ridge National Laboratory (25 years), then Professor and Senior Biological Sciences Research Member at Claude Pepper Institute for Aging and Therapeutic Research in Melbourne, Fla. Dr. Regan will be Director of the Scientific Advisory Board (SAB). He will join Dr. Danilo Lasic (formerly Senior Scientist at Sequus Pharmaceutical Company, which recently merged with Alza) in developing expanded liposome drug products. Most prominent will be the development of Vascular Endothelial Growth Factor (VEGF) therapeutic protein for promoting growth of new blood vessels in patients' hearts that have developed severe blood-oxygen deficiencies. "The objective is to improve myocardial perfusion," said Dr. David Summers, chairman and CEO. "Preliminary clinical evidence suggests that therapeutic angiogenesis may become a very useful treatment strategy for patients with severe heart disease. Our goal is to deliver the protein in liposomes or microspheres which add the benefits of stability and chronic release."

Also appointed to the SAB was Hiroko Yoshida Ph.D., a Physical Chemist whose specialty is molecular bindings to DNA, kinetics of binding and hydrolysis, and conformation of biomolecular adducts. Formerly with Armed Forces Radiobiology Research Institute, the Oak Ridge National Laboratories where she did research in radiation chemistry of DNA and polyamino acids, she joined Claude Pepper Institute of Aging and Therapeutic Research in 1993. Dr. Yoshida is a Registered Nurse who received her Ph.D. in Chemistry from New York University in 1978. She continues as a consultant for the Japan Environmental Assessment Center in Tokyo, Japan, and publishes in both English and Japanese. Dr. Yoshida will become responsible for the company's ongoing biodegradable coatings for prosthesis including stents and orthopedic implants project using Liprostin(TM), the company's new liposomal prostaglandin E-1 (PGE-1). She will also work with Liprostin(TM) in parenteral form for treatment of critical limb ischemia (CLI).

"We are breaking new barriers," stated Dr. Summers. "Today's drug delivery companies are expected to deliver a drug that achieves the desired level of therapeutic activity quickly. This is already a $12 billion market and will grow to $200 billion in less than 10 years. Our two new appointments are of the world-class we need to become a major participant in this market."

About the Company

Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in the generic form. The company's products and processes are covered by patents and trade secrets for competing in a $2 billion market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.